Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 4/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367913 | 0.85 | DPP4 (0.55) | SCN4ADPP4F2GBA1GRIN2D | |
| SCHEMBL2521653 | 0.85 | DPP4 (0.55) | SCN4ADPP4F2GBA1GRIN2D | |
| SCHEMBL6859189 | 0.85 | DPP4 (0.55) | SCN4ADPP4F2GBA1GRIN2D | |
| SCHEMBL6859196 | 0.85 | DPP4 (0.55) | SCN4ADPP4F2GBA1GRIN2D | |
| SCHEMBL22338073 | 0.79 | IDO1 (0.41) | DPP4TAAR1 | |
| SCHEMBL5914545 | 0.76 | TAAR1 (0.48) | SCN4ADPP4F2TAAR1 | |
| SCHEMBL6856102 | 0.76 | TAAR1 (0.48) | SCN4ADPP4F2TAAR1 | |
| SCHEMBL13995085 | 0.76 | TAAR1 (0.48) | SCN4ADPP4F2TAAR1 | |
| SCHEMBL28853589 | 0.76 | SCN4A (0.47) | SCN4ADPP4F2GBA1GRIN2D | |
| SCHEMBL11415966 | 0.76 | TAAR1 (0.48) | SCN4ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450528-B2 | Process for the preparation of 2,2-difluoroethylamine starting from a benzylamine compound | BAYER CROPSCIENCE AG (DE) | 2013-05-28 | — | — | US | disclosed |
| US-20120123163-A1 | PROCESS FOR THE PREPARATION OF 2,2-DIFLUOROETHYLAMINE STARTING FROM A BENZYLAMINE COMPOUND | BAYER CROPSCIENCE AG (DE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123163-A1 | PROCESS FOR THE PREPARATION OF 2,2-DIFLUOROETHYLAMINE STARTING FROM A BENZYLAMINE COMPOUND | HDHD5, CTRB2, H1-2 | SCN4A 2003/4885DPP4 4308/4885F2 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.